Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
EO2463 is a cancer vaccine comprised of microbiome-derived peptides homologous to tumor-associated antigens (TAA), which when presented by dendritic cells may lead to activation of T-cell mediated immune response against the TAAs expressed on tumor cells (NCI Drug Dictionary).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|EO2463 + Lenalidomide + Rituximab||EO2463 Lenalidomide Rituximab||0||1|
|EO2463 + Rituximab||EO2463 Rituximab||0||1|